What type of study is this?

This is a Pre-Registered Trial study.

December 8, 2025BloodOpen Access

Recombinant ADAMTS13 prophylaxis in patients with congenital thrombotic thrombocytopenic purpura: Final analysis from A phase 3 randomized, controlled study

View Full Paper

Ask AI

Bookmark

Authors

JWJerzy WindygaInstytut Hematologii i Transfuzjologi KKKarim KentoucheRoyal London Hospital AAAna G. AntunEmory University

Discussion

Member takes

Implication

Phase 3 trial shows rADAMTS13 prophylaxis improves safety and efficacy in patients with congenital TTP, suggesting clinical benefit over plasma-based therapy.

Key Points

To evaluate the efficacy and safety of recombinant ADAMTS13 prophylaxis in patients with congenital thrombotic thrombocytopenic purpura.
Phase 3 randomized controlled trial design
Participants aged 0-70 with confirmed congenital TTP
Randomized to receive either rADAMTS13 or plasma-based therapy every 1-2 weeks
Treatment period of 6 months with crossover for another 6 months
Assessment of treatment satisfaction and adverse events
No acute TTP events during rADAMTS13 prophylaxis
Lower annualized event rates of TTP manifestations compared to plasma-based therapy
Higher treatment satisfaction scores reported for rADAMTS13
No serious treatment-related adverse events with rADAMTS13
Participants experienced fewer adverse events while on rADAMTS13

Cite This Study

Windyga et al. (2025) studied this question.

synapsesocial.com/papers/69362f6e4fa91c937236e166 https://doi.org/10.1182/blood-2025-848

View Full Paper

Ask AI

Bookmark

Implication

Phase 3 trial shows rADAMTS13 prophylaxis improves safety and efficacy in patients with congenital TTP, suggesting clinical benefit over plasma-based therapy.

Recombinant ADAMTS13 prophylaxis in patients with congenital thrombotic thrombocytopenic purpura: Final analysis from A phase 3 randomized, controlled study

Discussion

Member takes

Implication

Key Points

Cite This Study

Recombinant ADAMTS13 prophylaxis in patients with congenital thrombotic thrombocytopenic purpura: Final analysis from A phase 3 randomized, controlled study

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider